Preemptive antiviral therapy guided by quantitative real-time PCR assays (QRT-PCR) is currently the mainstay strategy for the prevention of CMV disease in allogeneic stem cell transplant (Allo-SCT) recipients. [1] [2] [3] [4] [5] The main drawback of this strategy is drug-related toxicity due to overtreatment, whose magnitude ultimately depends upon the CMV DNA load threshold chosen for triggering the initiation of antiviral therapy.
Out of the 67 episodes of active CMV infection, 27 (40%) were initial episodes, occurring at a median of 26 days (range, 5-56 days) following Allo-SCT, and 40 (60%) were recurrent episodes, developing at a median of 167 days (range, 32-723 days) after Allo-SCT. In all, 28 of the 67 episodes (42%) were preemptively treated with valganciclovir (10 were initial episodes and 18 were recurrences), and all but 3 (n = 25) resolved within the study period. The criterion for triggering the administration of valganciclovir was a CMV dt ⩽ 2.0 days (the novel strategy) in 12 episodes occurring in 7 patients (3 initial and 9 recurrent) and a CMV DNA load 41000 copies/mL (conventional strategy at our center) in 16 episodes (7 initial episodes and 9 recurrences occurring in 14 patients). CMV dts 42.0 days were observed in 5 out of the latter 16 episodes, whereas CMV dt could not be calculated in the remaining 11 episodes.
We established two groups for comparison purposes: group A, including episodes for which the novel strategy could be implemented (n = 12), and group B, including episodes that were treated according to our conventional protocol (n = 16). Univariate analyses (χ 2 test) showed that both groups were comparable in terms of pre-transplant factors that increase the risk for CMV end-organ disease (donor/recipient CMV serostatus, type of donor and HLA match; data not shown). In addition, the incidence of acute GvHD requiring corticosteroids treatment at high doses (41 mg/kg/day) before or during the episode of active CMV infection was also comparable between groups (P = 0.48). Moreover, episodes in groups A and B did develop within a comparable time frame (median of 82 days, range 17-723 days after transplant for episodes in group A, and a median of 149 days, range 8-599 days for episodes in group B; P = 0.50, Mann-Whitney U-test), and the frequency at which CMV DNA load monitoring was performed did not differ between episodes in both groups. Initial CMV DNA load values did not differ significantly between episodes in both study groups, whereas the median CMV DNA load at the time of treatment inception was significantly higher in episodes in group B, as expected (Table 2) . Overall, the duration of CMV DNAemia and the time on antiviral treatment were significantly lower in episodes in group A, regardless of whether these were initial or recurrent (Table 2) , and irrespective of whether a full or a reduced dose of valganciclovir was employed (P = 0.45). This effect was not due to differences between groups in terms of either the time to treatment initiation or the time elapsed between the first negative QRT-PCR result and treatment cessation (not shown). The reduction of the time on treatment was more pronounced in patients at high risk for CMV disease, these being those patients meeting one or more of the following conditions: unrelated or HLA-mismatched allograft, CMV-seropositive receiving an allograft from a CMV-seronegative donor, and treatment with high-dose corticosteroids for acute Abbreviations: CI = confidence interval; dt = doubling time. a The CMV dt was given by dt = (t 2 − t 1 ) × [log 2 /log(q 2 /q 1 )], with q 1 and t 1 representing the CMV DNA (copies/mL) at the time of the first positive QRT-PCR (in days), respectively, and q 2 and t 2 representing CMV DNA at the time of the second positive QRT-PCR. Only episodes in which there was an increase between the first and second CMV DNA load values of 43-fold were considered for analysis, the second value being o1000 copies/mL. In order to adhere strictly to our previous analyses, 7 dts were calculated exclusively in those episodes in which the first two plasma specimens testing positive by QRT-PCR were obtained less than 10 days apart. The time elapsed between the day of the first QRT-PCR-positive result to that of the second was a median of 4 days (range 2-9) for episodes with dts ⩽ 2 days and a median of 7 days (range 5-9 days) for episodes with dts 42 days. The CMV dt could not be calculated in 11 episodes because of either an increase between the first and second CMV DNA load values o3-fold, a single positive QRT-PCR result, first or second CMV DNA load 41000 copies/mL or time elapsed between the first and the second positive QRT-PCR results410 days. These episodes were treated following the conventional protocol, that is upon detection of 41000 CMV DNA copies/mL in plasma. Episodes with dts42 or those in which dt could not be calculated were treated following our standard protocol (upon detection of 41000 copies/mL). Differences between medians were compared using the Mann-Whitney U-test. A P value of o0.05 was considered statistically significant. e Time elapsed between the first positive QRT-PCR result and the time of CMV DNAemia clearance. Three episodes that were not cleared at the time of the patients's death were excluded from this analysis; thus, n = 25. Full dose of valganciclovir was used in 14 episodes and a reduced dose in the remaining 11 episodes.
f Competing risk regression analysis considering death as a competitive event for the occurrence of recurrent episodes of CMV DNAemia. This analysis was run using the statistical software R (http://www.r-project.org/). 15 g G-CSF was used in cases of severe neutropenia (o500 cells/μL). 
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GvHD (a median of 12 days vs a median of 8 days in the remaining patients; P = 0.03). As shown in Table 2 , the cumulative incidence of recurrences following episodes of active CMV infection managed by the novel approach was comparable to that observed after episodes that were preemptively treated following the conventional protocol. The follow-up time for annotating recurrent episodes was not significantly different in both groups (group A, median, 246 days; range 14-318 days; group B, median 195 days; range, 20-339 days; P = 0.99). Only one patient (episode with dt ⩽ 2.0 days) developed CMV end-organ disease (gastro-intestinal disease in the setting of a grade IV aGvHD). Finally, we assessed the incidence of drug-related toxicity (neutropenia and thrombocytopenia) in both groups. The neutrophil and platelet cell counts at the initiation of antiviral therapy were not significantly different among episodes in both groups ( Table 2 ). The use of G-CSF or platelet transfusion for severe neutropenia or thrombocytopenia, respectively, during valganciclovir therapy courses was comparable irrespective of the strategy deployed (Table 2) .
To our knowledge, this is the first reported experience of a preemptive antiviral therapy strategy for active CMV infection in Allo-SCT recipients guided by the viral dt. We showed that the inception of valganciclovir treatment upon detection of viral dts ⩽ 2 days led to shorter treatment courses when compared with that in episodes managed conventionally, irrespective of whether the episode of CMV DNAemia was either initial or recurrent, thus allowing cost savings. Our strategy did not lead to a higher incidence of recurrent episodes, and thus should not result in a higher incidence of early or late CMV end-organ disease. Nevertheless, a single case of CMV end-organ disease was diagnosed within an episode with dt ⩽ 2, so that definitive conclusions on this issue could not be drawn. This novel strategy did not appear to result in lower levels of drug-related toxicity (neutropenia/thrombocytopenia). Nevertheless, the small size of our cohort and the trend toward lower baseline platelet cell counts in episodes with dts ⩽ 2 precluded drawing firm conclusions on this matter. In addition, the relatively scarce number of episodes occurring early after transplant in our series, a time at which patients are more prone to developing valganciclovir-related hematological toxicity, drastically limited the likelihood of proving such a beneficial effect. A relevant issue to be considered is the fact that the use of kinetic analyses of CMV DNA load in the blood for guiding the initiation of antiviral therapy may allow for direct comparison of the experience gathered across transplant centers using different QRT-PCR assays, thus paving the way for setting universal consensus treatment thresholds. This is because most commercially available QRT-PCR assays show an exquisite linearity above their limit of quantification, with slope coefficients that vary minimally and approach R2 values of 1. 8, 9, 12 Despite the advent of international standards for CMV DNA quantification, such as the one made available by the World Health Organization, 13 this can hardly be achieved by using preestablished CMV DNA cutoff values, given the suboptimal across-center precision and reproducibility of both in-house or commercially available QRT-PCR. 14 In summary, in this proof-of-principle study, we showed that the CMV dt in the blood compartment might be a valuable parameter for guiding preemptive antiviral therapy for both initial and recurrent episodes of active CMV infection developing in a subset of Allo-SCT recipients, particularly in those at highest risk of CMV disease. The study cohort mostly included CMV-seropositive recipients receiving an allograft from CMV-seropositive donors and undergoing non-myeloablative conditioning. It remains to be determined whether our strategy yields comparable results in other Allo-SCT modalities (that is, cord blood transplants, T-cell-depleted allografts, myeloablative conditioning…). Further studies are warranted to validate this novel approach. In this sense, a randomized clinical trial directly comparing the above-described strategies (episodes with dts ⩽ 2.0 either managed with the novel or the conventional strategy and episodes with any dt managed with our the conventional program) is currently being designed.
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